Study of tagraxofusp reports 90 percent response rate for deadly blood cancer with no prior available therapies
An open-label, multi-cohort Phase II trial, led by investigators at The University of Texas MD Anderson Cancer Center, reports that treatment with the drug tagraxofusp resulted in high response rates in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare but highly aggressive – and often fatal bone marrow and blood disorder – for which there are no existing approved therapies.
Study findings were published...
Teen cancer patients prepare for an exciting night at annual Prom Party Palooza
HOUSTON – The University of Texas MD Anderson Children’s Cancer Hospital joins Peli Peli Restaurants, the National Association for Catering...
MD Anderson addresses national threat of foreign influence
The impact of foreign influence across multiple sectors of the United States economy continues to be a national concern. Specific to academia...
Triple negative breast cancers can adopt reversible state that is resistant to chemotherapy
Researchers at The University of Texas MD Anderson Cancer Center have discovered that triple negative breast cancer (TNBC) cells can develop resistance to frontline, or neoadjuvant, chemotherapy not by acquiring permanent adaptations, but rather transiently turning on molecular pathways that protect the cells.
The study, published today in Science Translational Medicine, also identifies a vulnerability that may provide a new treatment...
MD Anderson and Houston Dynamo to host End Cancer Night April 27
The University of Texas MD Anderson Cancer Center proudly presents End Cancer Night at BBVA Compass Stadium Saturday, April 27 at 7 p.m. as...